Preclinical Asset Market Report: Trends, Forecast and Competitive Analysis to 2030
Preclinical Asset Trends and Forecast
The future of the global preclinical asset market looks promising with opportunities in the biopharmaceutical company and government institute markets. The global preclinical asset market is expected to grow with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are increasing drug discovery activities, growing demand for personalized medicine, and rising launch of new toxicology tests by key market players.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Preclinical Asset by Segment
The study includes a forecast for the global preclinical asset by service type, model type, end use, and region.
Preclinical Asset Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies preclinical asset companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the preclinical asset companies profiled in this report include-
Lucintel forecasts that bioanalysis & DMPK is expected to witness highest growth over the forecast period.
Within this market, biopharmaceutical company will remain the largest segment.
North America is expected to witness highest growth over the forecast period due to growing number of inorganic strategies carried on by the key market players.
Features of the Global Preclinical Asset Market
Market Size Estimates: Preclinical asset market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Preclinical asset market size by service type, model type, end use, and region in terms of value ($B).
Regional Analysis: Preclinical asset market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different service types, model types, end uses, and regions for the preclinical asset market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the preclinical asset market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for preclinical asset market?
Answer: The global preclinical asset market is expected to grow with a CAGR of 7.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the preclinical asset market?
Answer: The major drivers for this market are increasing drug discovery activities, growing demand for personalized medicine, and rising launch of new toxicology tests by key market players.
Q3. What are the major segments for preclinical asset market?
Answer: The future of the preclinical asset market looks promising with opportunities in the biopharmaceutical company and government institute markets.
Q4. Who are the key preclinical asset market companies?
Answer: Some of the key preclinical asset companies are as follows:
Answer: Lucintel forecasts that bioanalysis & DMPK is expected to witness highest growth over the forecast period.
Q6. In preclinical asset market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to growing number of inorganic strategies carried on by the key market players.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the preclinical asset market by service type (bioanalysis & DMPK, toxicology testing, compound management, safety pharmacology, and others), model type (patient derived organoid model and patient derived xenograft model), end use (biopharmaceutical companies, government institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Preclinical Asset Market, Preclinical Asset Market Size, Preclinical Asset Market Growth, Preclinical Asset Market Analysis, Preclinical Asset Market Report, Preclinical Asset Market Share, Preclinical Asset Market Trends, Preclinical Asset Market Forecast, Preclinical Asset Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
The future of the global preclinical asset market looks promising with opportunities in the biopharmaceutical company and government institute markets. The global preclinical asset market is expected to grow with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are increasing drug discovery activities, growing demand for personalized medicine, and rising launch of new toxicology tests by key market players.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Preclinical Asset by Segment
The study includes a forecast for the global preclinical asset by service type, model type, end use, and region.
Preclinical Asset Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:
- Bioanalysis & DMPK (Drug Metabolism and Pharmacokinetic)
- Toxicology Testing
- Compound Management
- Safety Pharmacology
- Others
- Patient Derived Organoid Model
- Patient Derived Xenograft Model
- Biopharmaceutical Companies
- Government Institutes
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies preclinical asset companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the preclinical asset companies profiled in this report include-
- IQVIA
- ICON
- Eurofins Scientific
- PPD
- SGS
- Intertek
- Charles River Laboratories
- Medpace
- Pharmaron Beijing
- Evotec
Lucintel forecasts that bioanalysis & DMPK is expected to witness highest growth over the forecast period.
Within this market, biopharmaceutical company will remain the largest segment.
North America is expected to witness highest growth over the forecast period due to growing number of inorganic strategies carried on by the key market players.
Features of the Global Preclinical Asset Market
Market Size Estimates: Preclinical asset market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Preclinical asset market size by service type, model type, end use, and region in terms of value ($B).
Regional Analysis: Preclinical asset market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different service types, model types, end uses, and regions for the preclinical asset market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the preclinical asset market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for preclinical asset market?
Answer: The global preclinical asset market is expected to grow with a CAGR of 7.8% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the preclinical asset market?
Answer: The major drivers for this market are increasing drug discovery activities, growing demand for personalized medicine, and rising launch of new toxicology tests by key market players.
Q3. What are the major segments for preclinical asset market?
Answer: The future of the preclinical asset market looks promising with opportunities in the biopharmaceutical company and government institute markets.
Q4. Who are the key preclinical asset market companies?
Answer: Some of the key preclinical asset companies are as follows:
- IQVIA
- ICON
- Eurofins Scientific
- PPD
- SGS
- Intertek
- Charles River Laboratories
- Medpace
- Pharmaron Beijing
- Evotec
Answer: Lucintel forecasts that bioanalysis & DMPK is expected to witness highest growth over the forecast period.
Q6. In preclinical asset market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to growing number of inorganic strategies carried on by the key market players.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the preclinical asset market by service type (bioanalysis & DMPK, toxicology testing, compound management, safety pharmacology, and others), model type (patient derived organoid model and patient derived xenograft model), end use (biopharmaceutical companies, government institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Preclinical Asset Market, Preclinical Asset Market Size, Preclinical Asset Market Growth, Preclinical Asset Market Analysis, Preclinical Asset Market Report, Preclinical Asset Market Share, Preclinical Asset Market Trends, Preclinical Asset Market Forecast, Preclinical Asset Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL PRECLINICAL ASSET MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Preclinical Asset Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Preclinical Asset Market by Service Type
3.3.1: Bioanalysis & DMPK (Drug Metabolism and Pharmacokinetic)
3.3.2: Toxicology Testing
3.3.3: Compound Management
3.3.4: Safety Pharmacology
3.3.5: Others
3.4: Global Preclinical Asset Market by Model Type
3.4.1: Patient Derived Organoid Model
3.4.2: Patient Derived Xenograft Model
3.5: Global Preclinical Asset Market by End Use
3.5.1: Biopharmaceutical Companies
3.5.2: Government Institutes
3.5.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Preclinical Asset Market by Region
4.2: North American Preclinical Asset Market
4.2.1: North American Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.2.2: North American Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.3: European Preclinical Asset Market
4.3.1: European Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.3.2: European Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.4: APAC Preclinical Asset Market
4.4.1: APAC Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.4.2: APAC Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.5: ROW Preclinical Asset Market
4.5.1: ROW Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.5.2: ROW Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Preclinical Asset Market by Service Type
6.1.2: Growth Opportunities for the Global Preclinical Asset Market by Model Type
6.1.3: Growth Opportunities for the Global Preclinical Asset Market by End Use
6.1.4: Growth Opportunities for the Global Preclinical Asset Market by Region
6.2: Emerging Trends in the Global Preclinical Asset Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Preclinical Asset Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Preclinical Asset Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: IQVIA
7.2: ICON
7.3: Eurofins Scientific
7.4: PPD
7.5: SGS
7.6: Intertek
7.7: Charles River Laboratories
7.8: Medpace
7.9: Pharmaron Beijing
7.10: Evotec
2. GLOBAL PRECLINICAL ASSET MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Preclinical Asset Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Preclinical Asset Market by Service Type
3.3.1: Bioanalysis & DMPK (Drug Metabolism and Pharmacokinetic)
3.3.2: Toxicology Testing
3.3.3: Compound Management
3.3.4: Safety Pharmacology
3.3.5: Others
3.4: Global Preclinical Asset Market by Model Type
3.4.1: Patient Derived Organoid Model
3.4.2: Patient Derived Xenograft Model
3.5: Global Preclinical Asset Market by End Use
3.5.1: Biopharmaceutical Companies
3.5.2: Government Institutes
3.5.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Preclinical Asset Market by Region
4.2: North American Preclinical Asset Market
4.2.1: North American Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.2.2: North American Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.3: European Preclinical Asset Market
4.3.1: European Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.3.2: European Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.4: APAC Preclinical Asset Market
4.4.1: APAC Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.4.2: APAC Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
4.5: ROW Preclinical Asset Market
4.5.1: ROW Preclinical Asset Market by Service Type: Bioanalysis and DMPK, Toxicology Testing, Compound Management, Safety Pharmacology, and Others
4.5.2: ROW Preclinical Asset Market by End Use: Biopharmaceutical Companies, Government Institutes, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Preclinical Asset Market by Service Type
6.1.2: Growth Opportunities for the Global Preclinical Asset Market by Model Type
6.1.3: Growth Opportunities for the Global Preclinical Asset Market by End Use
6.1.4: Growth Opportunities for the Global Preclinical Asset Market by Region
6.2: Emerging Trends in the Global Preclinical Asset Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Preclinical Asset Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Preclinical Asset Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: IQVIA
7.2: ICON
7.3: Eurofins Scientific
7.4: PPD
7.5: SGS
7.6: Intertek
7.7: Charles River Laboratories
7.8: Medpace
7.9: Pharmaron Beijing
7.10: Evotec
